CGTX
Cognition Therapeutics, Inc. NASDAQ Listed Oct 8, 2021$0.94
-1.50%
vs $0.95
Mkt Cap $83.8M
52w Low $0.55
25.8% of range
52w High $2.05
50d MA $1.00
200d MA $1.15
P/E (TTM)
—
EV/EBITDA
—
P/B
2.0x
Debt/Equity
0.0x
ROE
-68.5%
P/FCF
-2.8x
RSI (14)
33.00
ATR (14)
$0.05
Beta
1.40
50d MA
$1.00
200d MA
$1.15
Avg Volume
407.0K
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
CIK (SEC)
Phone
412 481 2210
2500 Westchester Avenue · Purchase, NY 10577 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.06 | -0.02 | +66.7% | 1.08 | -0.9% | -32.4% | -18.6% | +27.7% | +17.4% | -2.6% | — |
| Nov 6, 2025 | AMC | -0.07 | -0.06 | +14.3% | 1.66 | +0.0% | +0.0% | +1.2% | +4.2% | -1.7% | -10.5% | — |
| Aug 7, 2025 | AMC | -0.12 | -0.11 | +8.3% | 0.68 | -0.2% | +11.4% | +13.8% | +28.1% | +10.9% | +36.1% | — |
| May 7, 2025 | AMC | -0.12 | -0.14 | -16.7% | 0.35 | -1.3% | -7.0% | -8.8% | +8.6% | -1.7% | +3.8% | — |
| Mar 20, 2025 | AMC | -0.16 | -0.17 | -6.2% | 0.43 | -1.6% | +6.6% | +7.7% | -6.2% | -3.9% | +2.1% | — |
| Nov 13, 2024 | AMC | -0.24 | -0.25 | -4.2% | 0.54 | -1.3% | -4.7% | -9.9% | +0.3% | -4.0% | -0.9% | — |
| Aug 8, 2024 | AMC | -0.22 | -0.18 | +18.2% | 0.58 | +2.2% | -6.4% | +3.9% | +3.8% | +4.4% | +4.3% | — |
| May 7, 2024 | AMC | -0.23 | -0.27 | -17.4% | 1.92 | +1.6% | +4.2% | -4.5% | +1.6% | +0.5% | +1.5% | — |
| Mar 26, 2024 | AMC | -0.38 | -0.27 | +28.9% | 1.83 | +2.7% | -0.5% | +0.0% | +4.4% | -4.7% | +8.8% | — |
| Nov 2, 2023 | AMC | -0.31 | -0.22 | +29.0% | 1.02 | +3.9% | +3.9% | +0.0% | -1.9% | +9.6% | -12.3% | — |
| Aug 8, 2023 | AMC | -0.25 | -0.16 | +36.0% | 1.72 | +3.5% | +0.0% | -2.3% | -4.8% | -4.4% | -2.6% | — |
| May 4, 2023 | AMC | -0.17 | -0.21 | -23.5% | 1.67 | +1.8% | -6.6% | +3.2% | +0.0% | -2.5% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $1.08 | $1.07 | -0.9% | -32.4% | -18.6% | +27.7% | +17.4% | -2.6% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | -2.2% | -1.7% | +1.2% | -4.0% | +0.6% |
| Nov 21 | B. Riley Securities | Maintains | Buy → Buy | — | $1.33 | $1.36 | +2.3% | +4.5% | +10.1% | -4.6% | +13.0% | +5.5% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.51 | -0.7% | -8.6% | -4.3% | +4.5% | +10.1% | -4.6% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $0.68 | $0.68 | -0.2% | +11.4% | +13.8% | +28.1% | +10.9% | +36.1% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.30 | $0.31 | +3.6% | +8.2% | -7.6% | +3.3% | +0.8% | +7.3% |
| May 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.30 | $0.30 | +0.5% | -12.9% | -5.8% | +2.1% | -3.9% | +32.6% |
| May 8 | Chardan Capital | Maintains | Buy → Buy | — | $0.35 | $0.35 | -1.3% | -7.0% | -8.8% | +8.6% | -1.7% | +3.8% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.45 | $0.45 | -1.1% | +7.7% | -6.2% | -3.9% | +2.1% | -7.8% |
| Mar 21 | Chardan Capital | Maintains | Buy → Buy | — | $0.43 | $0.42 | -1.6% | +6.6% | +7.7% | -6.2% | -3.9% | +2.1% |
| Feb 26 | Chardan Capital | Maintains | Buy → Buy | — | $0.52 | $0.50 | -2.6% | -4.2% | -7.4% | -0.7% | -5.4% | -2.3% |
| Dec 19 | Chardan Capital | Maintains | Buy → Buy | — | $0.58 | $0.65 | +11.5% | +9.3% | -0.6% | -2.6% | +5.5% | +18.4% |
| Dec 19 | B. Riley Securities | Upgrade | Neutral → Buy | — | $0.58 | $0.65 | +11.5% | +9.3% | -0.6% | -2.6% | +5.5% | +18.4% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.58 | $0.65 | +11.5% | +9.3% | -0.6% | -2.6% | +5.5% | +18.4% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.40 | $0.41 | +0.1% | -1.6% | +1.0% | -0.5% | -3.3% | -1.8% |
| Nov 15 | Chardan Capital | Maintains | Buy → Buy | — | $0.51 | $0.50 | -2.3% | -9.9% | +0.3% | -4.0% | -0.9% | -0.0% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.47 | $0.47 | +0.0% | +0.7% | +2.9% | +2.4% | +4.1% | -2.9% |
| Oct 31 | Chardan Capital | Maintains | Buy → Buy | — | $0.53 | $0.52 | -2.1% | -11.1% | -0.3% | +0.7% | +2.9% | +2.4% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.55 | $0.55 | +0.8% | +3.9% | +3.8% | +4.4% | +4.3% | +10.6% |
| Aug 6 | B. Riley Securities | Downgrade | Buy → Neutral | — | $0.66 | $0.66 | +0.0% | -1.7% | -9.8% | +0.5% | -6.4% | +3.9% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.00 | $0.97 | -3.0% | -10.0% | -19.0% | -10.0% | -1.7% | -9.8% |
| Jul 30 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $1.33 | $1.10 | -17.3% | -17.3% | -9.1% | -10.0% | -19.0% | -10.0% |
| Jul 2 | Rodman & Renshaw | Maintains | Buy → Buy | — | $1.67 | $1.75 | +4.8% | +9.0% | -2.7% | +7.9% | -1.6% | +9.6% |
| Mar 28 | B. Riley Securities | Maintains | Buy → Buy | — | $1.82 | $1.81 | -0.5% | +0.0% | +4.4% | -4.7% | +8.8% | -2.0% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.83 | $1.88 | +2.7% | -0.5% | +0.0% | +4.4% | -4.7% | +8.8% |
| Aug 14 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $1.60 | $1.61 | +0.6% | -4.4% | -2.6% | +3.4% | -1.3% | +0.7% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.61 | $1.63 | +1.2% | +0.0% | -2.5% | +1.3% | +0.6% | +6.9% |
| Mar 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.83 | $1.79 | -2.2% | +6.0% | +7.7% | -2.4% | -2.5% | -2.5% |
| Sep 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.74 | $1.89 | +8.6% | +13.8% | -4.0% | -4.7% | +6.1% | +3.1% |
| Apr 22 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $3.10 | $3.34 | +7.7% | +1.6% | -3.2% | -7.5% | +2.8% | -0.7% |
| Nov 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.21 | $12.71 | +4.1% | +2.6% | -1.0% | -3.1% | +0.9% | +7.0% |
No insider trades available.
8-K · 8.01
!! High
Cognition Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 24
8-K
Cognition Therapeutics, Inc. -- 8-K Filing
Jun 18
8-K · 7.01
! Medium
Cognition Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 4
8-K · 8.01
!! High
Cognition Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 21
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CGTX issued a press release on March 26, 2026, signaling potential material news that investors should review immediately, as 8-K filings typically disclose significant corporate developments affecting stock valuation.
Mar 26
8-K · 8.01
!! High
Cognition Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cognition Therapeutics filed a material event announcement via press release, though the specific details require reviewing the attached exhibit to understand the announcement's impact on investors.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bios Capital Management, Lp | 6,000,000 | $7M | — | Jun 2026 |
| 2 | Davenport & Co Llc | 4,259,511 | $5M | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 3,438,775 | $4M | Added | Jun 2026 |
| 4 | Blackrock, Inc. | 1,261,993 | $1M | New | Jun 2026 |
| 5 | Jane Street Group, Llc | 614,261 | $829K | Reduced | Dec 2025 |
| 6 | Renaissance Technologies Llc | 693,288 | $797K | Reduced | Jun 2026 |
| 7 | Cm Management, Llc | 450,000 | $518K | Added | Jun 2026 |
| 8 | Dauntless Investment Group, Llc | 371,701 | $427K | Reduced | Jun 2026 |
| 9 | Hilton Capital Management, Llc | 548,950 | $417K | — | Mar 2026 |
| 10 | Sigma Planning Corp | 216,165 | $295K | Added | Dec 2025 |
| 11 | Morgan Stanley | 186,656 | $252K | Added | Dec 2025 |
| 12 | American Financial Group Inc | 205,000 | $156K | — | Mar 2026 |
| 13 | Voss Capital, Lp | 200,000 | $152K | Reduced | Mar 2026 |
| 14 | Tocqueville Asset Management L.p. | 195,000 | $148K | Added | Mar 2026 |
| 15 | Northern Trust Corp | 168,686 | $128K | Reduced | Mar 2026 |
| 16 | Hrt Financial Lp | 152,999 | $116K | New | Mar 2026 |
| 17 | Susquehanna International Group, Llp | 80,663 | $61K | Added | Mar 2026 |
| 18 | Fca Corp /tx | 52,536 | $60K | — | Jun 2026 |
| 19 | Ubs Group Ag | 76,873 | $58K | Added | Mar 2026 |
| 20 | Empirical Financial Services, Llc D.b.a. Empirical Wealth Management | 48,000 | $55K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 421,387 | $459K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 143,771 | $170K | May 2026 |
| 3 | Fidelity Series Total Market Index Fund | 118,702 | $140K | May 2026 |
| 4 | Schwab Total Stock Market Index Fund | 84,940 | $93K | Jan 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 51,054 | $56K | Feb 2026 |
| 6 | Gabelli Global Mini Mites Fund | 30,000 | $23K | Mar 2026 |
| 7 | Victory Extended Market Index Fund | 8,212 | $9K | Jan 2026 |
| 8 | iShares Neuroscience and Healthcare ETF | 4,543 | $4K | Jul 2026 |
| 9 | Blackstone Alternative Multi-Strategy Fund | -27,700 | $-31855 | Jun 2026 |
Valuation
Market Cap
$83.8M
Enterprise Value
$31.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.07x
P/B
1.99x
P/S
—
P/FCF
-2.77x
EV/EBITDA
—
Shares Out
72.8M
Financials (TTM)
Revenue
$0
Net Income
-$16.8M
EBITDA
-$16.6M
Free Cash Flow
-$24.6M
Op Cash Flow
-$24.6M
EPS Basic
$-0.32
EPS Diluted
$-0.19
EPS Forward
$-0.32
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$48.4M
Total Liab.
$14.1M
Total Equity
$34.3M
Cash
$36.8M
LT Debt
$0
Book Value/Sh
$0.47
Debt/Equity
0.02x
Current Ratio
3.45
Quick Ratio
3.45
Returns & Growth
ROE
-68.5%
ROA
-48.5%
ROIC
-136.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
+62.4%
Price Returns
2W
-4.7%
1M
-10.8%
3M
-16.4%
6M
-13.3%
12M
-29.6%
Technicals
52W High
$2.05
52W Low
$0.55
50d MA
$1.00
200d MA
$1.15
RSI (14)
33.00
ATR (14)
$0.05
Beta
1.40
Avg Volume
407K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 1:02am
· Source: financialmodelingprep.com